Annovis Bio, Inc. (ANVS) company profile

Annovis Bio is a late-stage clinical drug platform company that discovers and develops therapeutics targeting neurodegenerative conditions, primarily Alzheimer’s disease and Parkinson’s disease. The company's lead drug candidate is buntanetap, an orally administered, brain-penetrant small molecule designed to inhibit the synthesis of neurotoxic aggregating proteins that disrupt nerve cell communication. Its clinical pipeline also features ANVS405, an intravenous formulation targeting acute indications such as traumatic brain injury and stroke, and ANVS301, an oral compound focused on advanced Alzheimer’s disease. As a clinical-stage biotechnology firm, the company directs its investigative treatments toward patients suffering from chronic and acute neurodegenerative disorders.

The company operates primarily across clinical research locations in the United States and Europe. Its clinical trials have spanned eighty-three trial sites in the United States for Alzheimer’s disease programs and fifty-three domestic sites alongside forty-nine sites in the European Union for Parkinson’s disease studies. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Annovis Bio's latest annual report, written by StockData.

“Per Share Total ​ ​ ​ ​ ​ ​ ​ Initial public offering price $6.00 $ 12,000,000 Underwriting discounts and commissions(1) $0.42 $ 840,000 Proceeds to us, before expenses $5.58 $ 11,160,000 (1) Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the public offering price payab”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of February 28, 2026, we had eight full-time employees and also utilize the services of key part-time employees or consultants.”